NCT04844099View on ClinicalTrials.gov

Dihydroartemisinin-Piperaquine or Sulphadoxine-Pyrimethamine for the Chemoprevention of Malaria in Sickle Cell Anaemia

PHASE3CompletedINTERVENTIONAL
Enrollment

723

Participants

Timeline

Start Date

April 9, 2021

Primary Completion Date

June 30, 2023

Study Completion Date

July 12, 2023

Conditions
Sickle Cell Anemia in ChildrenMalaria
Interventions
DRUG

Dihydroartemisinin Piperaquine

Administered as dihydroartemisinin (20mg) and piperaquine (160 mg)

Trial Locations (3)

Unknown

Queen Elizabeth Hospital, Blantyre

Jinja Regional Referral hospital, Jinja

Kitgum General Hospital, Kitgum

All Listed Sponsors
collaborator

University of Bergen

OTHER

collaborator

University of Malawi

OTHER

collaborator

Makerere University

OTHER

collaborator

Indiana University

OTHER

collaborator

Global Health Uganda LTD

OTHER

lead

Liverpool School of Tropical Medicine

OTHER